BIO-NMD newsletter

More documents

Recommendations

Info

PAGE 8BIO-NMD NEWSLETTERConclusionBiobanks are making an important contribution to medical research. Increasinginvestment is being made into establishing these important repositories of information. Forexample, Germany has recently announced plans for a €210 million project which willcollect samples from 200,000 donors along with scans of the brain, heart and otherorgans of 40,000 of the subjects, using magnetic resonance imaging. 9 As moreinformation about patients/donors is held, tight regulation of the use of this databecomes more important than ever. In order for biobanking to be useful, donors must bewilling to participate. They must therefore feel confident that their own interests areprotected and that rigorous ethical guidelines have been followed.Websites used (last accessed 16 August 2010)1. http://www.eurordis.org/about-rare-diseases2. http://www.eurobiobank.org/en/information/info_institut.htm#objectives3. http://genome.wellcome.ac.uk/doc_WTX036455.html4. http://www.ukbiobank.ac.uk/assessment/takepart.php5. http://www.bio-nmd.eu/forPatients/6. http://society.guardian.co.uk/alderhey/story/0,,450736,00.html7. http://www.hta.gov.uk/legislationpoliciesandcodesofpractice/legislation/humantissueact.cfm8. http://jme.bmj.com/content/29/1/4.full9. http://bulletin.sciencebusiness.net/ebulletins/showissue.php3?page=/548/art/18712/To comment on this article, visit www.bio-nmd.euor email: catherine.turner@newcastle.ac.uk
BIO-NMD NEWSLETTERPAGE 9BIO-NMD is a Translational ResearchProject – What does this mean?Translational researchbridges the gapbetween laboratoryand patientScientists are constantly discovering more and more about thehuman body. We now understand more than ever the processeswhich keep us alive and well along with some of the things that gowrong causing disease or ill-health. Much of new discovery andtechnology comes from basic research which takes place in thelaboratories of academic institutions or companies around the world.However, harnessing this knowledge and turning new discoveries intouseful, marketable treatments of direct benefit to human health ismuch more difficult. Translational research aims to overcome thisproblem. It is research which turns new knowledge andunderstanding gained in the laboratory into meaningful therapies,drugs or preventative measures which are of direct benefit topatients. In short, it bridges the gap between laboratory and patient.BIO-NMD does this by trying to identify biomarkers which can bemeasured in patients’ blood or urine to tell doctors more about thetype of neuromuscular disease they have and the best treatmentprogramme for them. Biomarkers will also speed up the testing ofnew drugs which may be of direct benefit to patients’ health.
Page 1 and 2: ISSUE 1 SEPTEMBER 2010BIO-NMD newsl
Page 3 and 4: BIO-NMD NEWSLETTERPAGE 3Who is invo
Page 5 and 6: BIO-NMD NEWSLETTERPAGE 5Main Articl
Page 7: BIO-NMD NEWSLETTERPAGE 7Payment:In
Page 11 and 12: BIO-NMD NEWSLETTERPAGE 11Cure CMD a

BIO-NMD newsletter

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?